% | $
Quotes you view appear here for quick access.

The Walt Disney Company Message Board

edfiggy 36 posts  |  Last Activity: Jul 22, 2015 9:18 PM Member since: Jul 24, 2003
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to


    by lwe6638 Jul 21, 2015 4:43 PM
    edfiggy edfiggy Jul 22, 2015 9:18 PM Flag

    This stock has the tendency of moving ahead of the news. I am watching for volume (accumulation) with a slight upwards bias. Resistance is at 14 cents.

  • Reply to


    by lwe6638 Jul 21, 2015 4:43 PM
    edfiggy edfiggy Jul 21, 2015 9:17 PM Flag

    It is my understanding that the Gates Foundation might provide some funding for the purchase of Luviva in Kenya. That would be a huge step forward. If the program is as a large as I hope, it can lead to the roll out of Luviva to other African countries. Nigeria has already tested Luviva. Extremely encouraging. As a stated before, I think the stock is very attractive at current levels and financing was only possible because large orders are near. A large order from Kenya can easily double the stock price from these depressed levels.

  • Reply to

    Attractive at current price levels

    by edfiggy Jul 19, 2015 4:04 PM
    edfiggy edfiggy Jul 20, 2015 5:45 PM Flag

    Eventually even a blind pig finds an acorn.

  • Reply to

    Attractive at current price levels

    by edfiggy Jul 19, 2015 4:04 PM
    edfiggy edfiggy Jul 20, 2015 5:43 PM Flag

    GTHP continues to expect large international orders. Hopefully, the company can execute. I do not think the financing deal would be possible without these orders to be very close to reality. I hope to see an announcement soon to change the sentiment towards GTHP. People are cynical for good reasons, but I really do not think new investors would putting $4mm in GTHP without some certainty of new orders.

  • I understand GTHP trading at 8-10 cents after the FDA announcement earlier this year. Obviously, any chance for FDA approval is now a 2016-2017 event and the company was out of cash. BK was a likely scenario back then (maybe as high as 80 percent). However, since the bad news from the FDA, GTHP announced a large order from Turkey and completed financing that will enable the company to operate until Q4 of this year. With BK out of the question in 2015, investors should buy this beaten down stock. The catalyst will be orders going forward. The reason the company was able to get financing IMHO, is because large orders are expected sooner rather than later. I am critical of Gene "Any Day Now" Cartwright, but feel the large order from Turkey a couple months ago can not be ignored. As we wait for Mexico, Bangladesh, Nigeria, and Kenya orders current levels are attractive.

    Sentiment: Buy

  • Reply to

    Large order from Turkey announced this morning

    by lwe6638 Jun 10, 2015 9:45 AM
    edfiggy edfiggy Jun 10, 2015 10:02 AM Flag

    HUGE order. We only have about 20 machines in inventory. Finally time to get busy. This is a game changer. Finally the large order we desperately needed. Now with some luck we get some follow-up orders from Kenya and Bangladesh in 2 months.... Makes GTHP a buy at these levels IMHO. Now they can get bridge financing and the stock has finally bottomed.

  • Reply to

    Business Daily Africa

    by lwe6638 Jun 3, 2015 9:37 AM
    edfiggy edfiggy Jun 3, 2015 4:34 PM Flag

    My biggest loss on any stock for at least 8 years. Let's just say the CEO (Gene Cartwright) has at least grossly embellish the prospects of the company during his tenure. My worse spec ever. They should sell the technology but they will do some bridge financing instead with additional dilution. The stock might be reacting to be imminent news of additional financing and dilution. The only hope is a large order. Becoming increasingly doubtful at the present time. My bad for listening to Gene "Any Day Now" Cartwright. FDA approval is at least 18 months away, they are out of money, more dilution on the way, and so far no orders.

  • Reply to

    Doing Some Math

    by federalistno57 Jun 3, 2015 11:58 AM
    edfiggy edfiggy Jun 3, 2015 4:22 PM Flag

    GTHP sales the Luviva machines at a loss. The money is in the disposables.

  • Reply to

    Mgmt Choice.

    by edfiggy May 29, 2015 9:51 AM
    edfiggy edfiggy May 29, 2015 10:47 AM Flag

    Not an issue if they have large orders announcement in the pipeline very very soon. If they do not stop the madness and sale the technology.

  • Reply to

    Mgmt Choice.

    by edfiggy May 29, 2015 9:51 AM
    edfiggy edfiggy May 29, 2015 10:31 AM Flag

    If the company can announce shortly 1 or 2 large orders financing is a lot easier to handle. However, if Gene has no orders to announce he should announce the company is for sale. In my opinion those are the options. What is the point of further dilution if he has no orders.

  • edfiggy by edfiggy May 29, 2015 9:51 AM Flag

    Either you have some large orders to announce very soon or you need to sale the technology. Those are your options. Cartwright have discussed the opportunities with Kenya, Bangladesh, Turkey, Nigeria, Mexico, etc. Instead of doing your impersonation of Nero playing the harp as Rome is burning either announce some orders or sale the technology. So I hope Godot is knocking at the door and orders are coming soon. Anyhow, as Don Quixote (Gene) is charging against the windmills, your shareholders have no interest in playing the role of Sancho Panza.

  • Reply to

    Wouldn't it be nice to....

    by cytomotw May 27, 2015 1:17 PM
    edfiggy edfiggy May 28, 2015 9:29 AM Flag

    Obviously the company needs to raise cash. Let's hope GTHP can finally announce those large orders Cartwright keeps discussing. If the company can finally get one of two large orders (Kenya, Mexico, Bangladesh, Turkey, etc....) the future of the company can change drastically. If orders are not in the pipeline in June then GTHP should place the company on the selling block and get as much as they can for the technology.

  • Everything was going well with Guided Therapeutics Inc (OTCBB:GTHP, GTHP message board), until the company published its disastrous announcement on Tuesday.

    Needless to say that all GTHP enthusiasts were eagerly expecting the FDA's approval of the company's product. There was only one possible reaction from said investors when they were slapped with the announcement that said approval was not given.

    In spite of GTHP's reassuring words that the FDA simply wants more data “before granting approval”, many investors abandoned ship – and who could really blame them?

    Put simply - a lot depended on this approval. It was a crucial step on GTHP's road to profit, and now it has been delayed for who knows how long. Now, medical companies run into that sort of thing all the time, and to be honest, this turn of events would not be all that big of a deal, if the company's latest financial report didn't look like this:

    Cash and cash equivalents - $18 thousand
    Total current assets – $1.5 million
    Total current liabilities – $5.1 million
    Sales - $127 thousand
    Net loss - $1.2 million
    With so little cash on hand, GTHP can ill afford to wait any amount of time at all. By all accounts, it looks like it may be forced to rely on selling more stock to fund its operations, so prudent investors should probably look out for more dilution.

    The silver lining in this whole situation is that the other part of the report is actually not that disastrous – especially if you consider the fact that $714 thousand of the $1.2 million reported under “net loss” can be attributed to Change in fair value of warrants.

    It's up to investors to decide what to make of all these facts, but a word of warning is probably in order here. GTHP seems to be walking on thin ice, and with this latest delay, it now seems like said perilous walk just got extended – perhaps drastically.

  • Reply to


    by not_y2k May 19, 2015 7:20 PM
    edfiggy edfiggy May 19, 2015 7:26 PM Flag

    Yes sales "any day now" according to Gene. Oops he said that 6 months ago and we are still waiting for orders. He even double production capacity ahead of those "large orders"in the fall of 2014. Well we have the manufacturing capacity....

  • Sale the company to Imhoff or a private investor for @25 cents and call it a day. Let's see what Gene says tomorrow. We are down to the sample data is too small but another PMA will take too long IMHO. Curious what Gene will say about other paths to approval.

  • Reply to

    Still merely a pure FDA play...

    by cytomotw May 19, 2015 7:17 AM
    edfiggy edfiggy May 19, 2015 10:57 AM Flag

    Me too. Personally think an approval with "conditions" (best case) ahead of financing you might see 50 cents. 75 cents would be max IMHO. FDA next week but no one is adding here. Show me stock. Well we need good FDA move or stock dilution will make GTHP a sub 10 cents stock. I bought because of the product so I am hoping for good FDA news. FDA is on the brink of killing this company. What a shame.

  • edfiggy edfiggy May 18, 2015 10:08 PM Flag

    I believe GTHP paid the interest in the preferred shares with stock instead of cash.

  • Reply to

    Market Reaction to 10Q - yawn

    by weqdrprts May 14, 2015 9:54 AM
    edfiggy edfiggy May 15, 2015 4:33 PM Flag

    Sadly it very true. It is a FDA flip of the coin. They need path forward to approval to get decent financing. I am hoping for a conditional approval. I expect for the FDA to request a follow-up study. They can use the data they are gathering in Peru. It would be devastating if the FDA requested for GTHP to refile with the results from the new study. The only reason I am in the stock is because the balance and fair option is for the FDA to give GTHP an approval with conditions. Under that scenario the stock moves back to 50 cents and they can secure financing at favorable terms. Then it is up to Gene to start closing sales. I hope his last year at GTHP has taught him how to be more effective.

  • Reply to

    Orders - Where is the beef?

    by edfiggy May 11, 2015 5:02 PM
    edfiggy edfiggy May 11, 2015 9:22 PM Flag

    I am long GTHP. However, I am not blind to the repeated underperformance by Mr. Cartwright. He lacks experience (first time CEO) and has failed to deliver repeatedly. Numerous mistakes (doubling production) and inability to meet his own guidance regarding many tasks. We can discuss the facts regarding the "performance" of Mr. Cartwright. I do not care how many shares you have or not. I am open to discuss Mr. Cartwright's performance with you anytime. That is the real issue. I believe I am factual regarding the facts that indicate Mr. Cartwright's tenure so far is a complete failure.

  • Cartwright hyped Bangladesh and Kenya. After 6/7 months of hearing "any day now", GTHP announced the sale of 1 machine to Kenya. Now we have to wait at least 45-60 days to find out if we will get a follow-up order of any size. Wondering about Bangladesh. After all that hype are we going to get an order for 1 machine as well? Where are the large orders GTHP has repeatedly promised to investors? At the end of the day, we never seem to receive that large order from Kenya, Bangladesh, Nigeria or Mexico. Expect Cartwright to hype those territories during the conference call, but do not expect any orders of any significance. That is the pattern. Q1 will pretty horrible with sales declining sequentially quarter over quarter. So, no sales or orders but we get a FDA update it seems. FDA "Any day now" for sure and sales in late 2015... Imagine that it sounds like 2014... just keep moving when you will receive those orders and everything will be fine Gene. Hey, maybe it is time to double production again. We can borrow money from Toniquent at 18% or given them shares in case by some miracle we get a path forward from the FDA.

120.00-0.03(-0.02%)Jul 31 4:01 PMEDT